Publications
5808 Results
- Journal / Conference
- Journal of Clinical Oncology 34, 2016 (suppl; abstr LBA5503);American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral
- Year
- 2016
- Research Committee(s)
- Gynecologic
- Study Number(s)
- OV21
OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC)
- Journal / Conference
- American Society of Human Genetics Meeting (Oct 18-22, 2016, Vancouver, BC), poster presentation
- Year
- 2016
- Research Committee(s)
- Cancer Control, Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
- Study Number(s)
- S0000, SWOG-9217
A Genetic Contribution to Prostate Cancer Incidence in Men of African Ancestry
- Journal / Conference
- San Antonio Breast Cancer Symposium (Dec 6-10, 2016, San Antonio, TX), oral, #S3-05
- Year
- 2016
- Research Committee(s)
- Breast
Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
- Journal / Conference
- Blood Advances Dec 1(3):250-259
- Year
- 2016
- Research Committee(s)
- Leukemia
- PMID
- PMID29046900
- PMC
- PMC5642915
- Study Number(s)
- S0805
US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL
- Journal / Conference
- Annals of Oncology vol. 27, 2016 Supp 6,abst. 720PD; European Society for Medical Oncology (October 7-11, 2016, Copenhagen, Denmark), (Annals of Oncology), poster
- Year
- 2016
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/E3805
Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial
- Journal / Conference
- World Conference on Lung Cancer (Dec 4-7, 2016,Vienna, Austria), oral
- Year
- 2016
- Research Committee(s)
- Lung
- Study Number(s)
- S1400
Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic screening updates
- Journal / Conference
- World Conference on Lung Cancer (Dec 4-7, 2016,Vienna, Austria); poster
- Year
- 2016
- Research Committee(s)
- Lung
- Study Number(s)
- S0819
Role of KRAS mutation status in NSCLC patients treated on S0819, a phase II trial of chemotherapy with or without cetuximab
- Journal / Conference
- World Conference on Lung Cancer (Dec 4-7, 2016,Vienna, Austria); poster
- Year
- 2016
- Research Committee(s)
- Lung
- Study Number(s)
- S1403
Afatinib with or without cetuximab for first-line treatment of advanced EGFR-mutant NSCLC: Interim Results of SWOG S1403
- Journal / Conference
- Blood 2016 128:2782; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
- Year
- 2016
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/C10701
A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB Study 10701 (Alliance)
- Journal / Conference
- Journal of Clinical Oncology; DOI: 10.1200/JCO.2016.69.7979; online before print October 28, 2016
- Year
- 2016
- Research Committee(s)
- Lymphoma
- PMID
- PMID27069074
- PMC
- n/a - correspondence
- Study Number(s)
- S0816